Logo

Synthebio

Company

Primary tabs

About your organization / profile

Accelerator Application

The localized adiposity is a disease recognized by the WHO that affects 1.4 B people (3.3 B in 2030). Synthebio has developed, with CNRS experts, the Convergent Ultrasound technology that radically eliminates localized body fat excess (adiposity) and provides results never achieved until now: up to 5 cm. waistline reduction after one 20-minutes session. Synthebio has developed a non-invasive medical device, the Slimiser that also uses digital management of ultrasound, shape recognition based on based on IA, augmented reality guidance of the physician.
This medical device is being CE marked and should reach the market this year.
Dr. Kleinsinger runs Synthebio. He created and managed Optis - Eyegate Pharmaceuticals for 8 years, that went public and is listed on Nasdaq.
The body contouring market is huge (4 B€, 27 B€ in 2030), international and rapidly growing (19% per year). The goal is to develop a midsize company that could become a leader in the booming market of esthetic medicine.

News

Network (0)

There are no organizations in the network.